Thyroid cancer is the most common endocrine cancer, but its key oncogenic drivers remain undefined. In this study we identified the TYRO3 and AXL receptor tyrosine kinases as transcriptional targets of the chemokine CXCL12/SDF-1 in CXCR4-expressing thyroid cancer cells. Both receptors were constitutively expressed in thyroid cancer cell lines but not normal thyroid cells. AXL displayed high levels of tyrosine phosphorylation in most cancer cell lines due to constitutive expression of its ligand GAS6. In human thyroid carcinoma specimens, but not in normal thyroid tissues, AXL and GAS6 were often coexpressed. In cell lines expressing both receptors and ligand, blocking each receptor or ligand dramatically affected cell viability and decreased resistance to apoptotic stimuli. Stimulation of GAS6-negative cancer cells with GAS6 increased their proliferation and survival. Similarly, siRNA-mediated silencing of AXL inhibited cancer cell viability, invasiveness, and growth of tumor xenografts in nude mice. Our findings suggest that a TYRO3/AXL-GAS6 autocrine circuit sustains the malignant features of thyroid cancer cells and that targeting the circuit could offer a novel therapeutic approach in this cancer.

Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer / Avilla, Elvira; Guarino, Valentina; Visciano, Carla; Liotti, Federica; Svelto, M.; Krishnamoorthy, GNAMA PRAKASAM; Franco, R.; Melillo, ROSA MARINA. - In: CANCER RESEARCH. - ISSN 0008-5472. - 71:5(2011), pp. 1792-1804. [10.1158/0008-5472.CAN-10-2186]

Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer.

AVILLA, ELVIRA;GUARINO, VALENTINA;VISCIANO, CARLA;LIOTTI, FEDERICA;KRISHNAMOORTHY, GNAMA PRAKASAM;MELILLO, ROSA MARINA
2011

Abstract

Thyroid cancer is the most common endocrine cancer, but its key oncogenic drivers remain undefined. In this study we identified the TYRO3 and AXL receptor tyrosine kinases as transcriptional targets of the chemokine CXCL12/SDF-1 in CXCR4-expressing thyroid cancer cells. Both receptors were constitutively expressed in thyroid cancer cell lines but not normal thyroid cells. AXL displayed high levels of tyrosine phosphorylation in most cancer cell lines due to constitutive expression of its ligand GAS6. In human thyroid carcinoma specimens, but not in normal thyroid tissues, AXL and GAS6 were often coexpressed. In cell lines expressing both receptors and ligand, blocking each receptor or ligand dramatically affected cell viability and decreased resistance to apoptotic stimuli. Stimulation of GAS6-negative cancer cells with GAS6 increased their proliferation and survival. Similarly, siRNA-mediated silencing of AXL inhibited cancer cell viability, invasiveness, and growth of tumor xenografts in nude mice. Our findings suggest that a TYRO3/AXL-GAS6 autocrine circuit sustains the malignant features of thyroid cancer cells and that targeting the circuit could offer a novel therapeutic approach in this cancer.
2011
Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer / Avilla, Elvira; Guarino, Valentina; Visciano, Carla; Liotti, Federica; Svelto, M.; Krishnamoorthy, GNAMA PRAKASAM; Franco, R.; Melillo, ROSA MARINA. - In: CANCER RESEARCH. - ISSN 0008-5472. - 71:5(2011), pp. 1792-1804. [10.1158/0008-5472.CAN-10-2186]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/393990
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 84
  • ???jsp.display-item.citation.isi??? 78
social impact